Cargando…

Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers

Mass vaccination campaigns are important to control the COVID-19 pandemic, however, adverse events (AEs) contribute to vaccine hesitancy. To investigate and compare early AEs between the BNT162b2 mRNA and AZD1222 adenovirus-vectored vaccines, recipients completed daily surveys about local and system...

Descripción completa

Detalles Bibliográficos
Autores principales: Wi, Yu-Mi, Kim, Si-Ho, Peck, Kyong-Ran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402750/
https://www.ncbi.nlm.nih.gov/pubmed/34452055
http://dx.doi.org/10.3390/vaccines9080931
_version_ 1783745865531260928
author Wi, Yu-Mi
Kim, Si-Ho
Peck, Kyong-Ran
author_facet Wi, Yu-Mi
Kim, Si-Ho
Peck, Kyong-Ran
author_sort Wi, Yu-Mi
collection PubMed
description Mass vaccination campaigns are important to control the COVID-19 pandemic, however, adverse events (AEs) contribute to vaccine hesitancy. To investigate and compare early AEs between the BNT162b2 mRNA and AZD1222 adenovirus-vectored vaccines, recipients completed daily surveys about local and systemic reactions for 7 days after each dose, respectively. A total of 80 and 1440 healthcare workers received two doses of BNT162b2 and a first dose of AZD1222 vaccines. Any AEs were reported by 52.5% of recipients after the first dose of BNT162b2, by 76.2% after the second dose of BNT162b2, and by 90.9% after the first dose of AZD1222 (p < 0.001). Younger vaccinees had more AEs after the second dose of BNT162b2 and first dose of AZD1222. Sex based differences were only observed in the AZD1222 recipient group. No incidence of anaphylaxis or neurologic AEs were observed. In conclusion, early AEs were mostly mild to moderate in severity and generally transient in both BNT162b2 and AZD1222 groups. Sufficient explanation of the expected AEs of the vaccine would be helpful for wider vaccination.
format Online
Article
Text
id pubmed-8402750
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84027502021-08-29 Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers Wi, Yu-Mi Kim, Si-Ho Peck, Kyong-Ran Vaccines (Basel) Article Mass vaccination campaigns are important to control the COVID-19 pandemic, however, adverse events (AEs) contribute to vaccine hesitancy. To investigate and compare early AEs between the BNT162b2 mRNA and AZD1222 adenovirus-vectored vaccines, recipients completed daily surveys about local and systemic reactions for 7 days after each dose, respectively. A total of 80 and 1440 healthcare workers received two doses of BNT162b2 and a first dose of AZD1222 vaccines. Any AEs were reported by 52.5% of recipients after the first dose of BNT162b2, by 76.2% after the second dose of BNT162b2, and by 90.9% after the first dose of AZD1222 (p < 0.001). Younger vaccinees had more AEs after the second dose of BNT162b2 and first dose of AZD1222. Sex based differences were only observed in the AZD1222 recipient group. No incidence of anaphylaxis or neurologic AEs were observed. In conclusion, early AEs were mostly mild to moderate in severity and generally transient in both BNT162b2 and AZD1222 groups. Sufficient explanation of the expected AEs of the vaccine would be helpful for wider vaccination. MDPI 2021-08-21 /pmc/articles/PMC8402750/ /pubmed/34452055 http://dx.doi.org/10.3390/vaccines9080931 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wi, Yu-Mi
Kim, Si-Ho
Peck, Kyong-Ran
Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers
title Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers
title_full Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers
title_fullStr Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers
title_full_unstemmed Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers
title_short Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers
title_sort early adverse events between mrna and adenovirus-vectored covid-19 vaccines in healthcare workers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402750/
https://www.ncbi.nlm.nih.gov/pubmed/34452055
http://dx.doi.org/10.3390/vaccines9080931
work_keys_str_mv AT wiyumi earlyadverseeventsbetweenmrnaandadenovirusvectoredcovid19vaccinesinhealthcareworkers
AT kimsiho earlyadverseeventsbetweenmrnaandadenovirusvectoredcovid19vaccinesinhealthcareworkers
AT peckkyongran earlyadverseeventsbetweenmrnaandadenovirusvectoredcovid19vaccinesinhealthcareworkers